Novavax Inc (NVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novavax Inc (NVAX) Competitors
The companies most similar to Novavax are Vir Biotechnology (VIR), Innoviva (INVA) and Nuvation Bio (NUVB). By market cap, Novavax ranks 7th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B.
Peer Comparison
NVAX's ROIC of -66.6% is below the peer median of -23.5%, and its revenue growth of -3.0% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Novavax (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Maravai Lifesciences Holdings Inc (MRVI) | $1.96B | N/A | 5.2x | -30.8% | -28.3% | 10.1% | 0.00% |
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pharvaris BV (PHVS) | $2.36B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Peer median | $1.38B | 5.8x | 5.2x | 0.0% | -23.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Novavax, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Maravai Lifesciences Holdings Inc (MRVI) | Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines... | MRVI competitors |
| Nektar Therapeutics (NKTR) | Nektar Therapeutics is a biopharmaceutical company. | NKTR competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Pharvaris BV (PHVS) | Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. | PHVS competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
Frequently Asked Questions About NVAX
Who are Novavax's main competitors?
The companies most similar to Novavax include Vir Biotechnology (VIR), Innoviva (INVA), Nuvation Bio (NUVB), CureVac NV (CVAC) and Nurix Therapeutics (NRIX), listed from the closest match.
Who is Novavax's biggest competitor?
Pharvaris BV (PHVS) is the largest of the similar companies at $2.36B; Vir Biotechnology (VIR) is the closest match by business profile, size, sector and industry.
How does NVAX stock compare with its competitors?
NVAX's P/S is 3.2x against a peer median of 5.2x; its net margin is -18.6% against a peer median of 0.0%.
Which of Novavax's competitors pays a higher dividend?
Novavax pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Novavax bigger than its competitors?
No. Novavax is 7th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.
NVAX pages: Overview, Earnings, Forecast, Financials, Competitors